{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:01:38Z","timestamp":1774364498975,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00108-025-02016-x","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T15:10:11Z","timestamp":1762701011000},"page":"480-488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aldosteronsynthaseinhibitoren: eine neue Medikamentegruppe f\u00fcr die Blutdruckbeeinflussung im Renin-Angiotensin-Aldosteron-System","Aldosterone synthase inhibitors: a\u00a0new group of drugs for influencing blood pressure in the renin-angiotensin-aldosterone system"],"prefix":"10.1007","volume":"67","author":[{"given":"Markus","family":"van der Giet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"key":"2016_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","volume":"94","author":"S Patel","year":"2017","unstructured":"Patel\u00a0S et\u00a0al (2017) Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomed Pharmacother 94:317\u2013325","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"2016_CR2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","volume":"80","author":"M Epstein","year":"2022","unstructured":"Epstein\u00a0M et\u00a0al (2022) Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A\u00a0Review of Evolving Treatment Paradigms. Am J Kidney Dis 80(5):658\u2013666","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"2016_CR3","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","volume":"79","author":"F Buffolo","year":"2022","unstructured":"Buffolo\u00a0F et\u00a0al (2022) Aldosterone as a\u00a0Mediator of Cardiovascular Damage. Hypertension 79(9):1899\u20131911","journal-title":"Hypertension"},{"key":"2016_CR4","doi-asserted-by":"publisher","first-page":"1226458","DOI":"10.3389\/fendo.2023.1226458","volume":"14","author":"X Li","year":"2023","unstructured":"Li\u00a0X et\u00a0al (2023) G protein-coupled estrogen receptor: a\u00a0promising therapeutic target for aldosterone-induced hypertension. Front Endocrinol 14:1226458","journal-title":"Front Endocrinol"},{"issue":"1","key":"2016_CR5","doi-asserted-by":"publisher","first-page":"T107","DOI":"10.1530\/JOE-16-0659","volume":"234","author":"S Ruhs","year":"2017","unstructured":"Ruhs\u00a0S et\u00a0al (2017) 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Nongenomic effects via the mineralocorticoid receptor. J\u00a0Endocrinol 234(1):T107\u2013T124","journal-title":"J Endocrinol"},{"issue":"12","key":"2016_CR6","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia\u00a0G et\u00a0al (2023) 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J\u00a0Hypertens 41(12):1874\u20132071","journal-title":"J Hypertens"},{"issue":"1","key":"2016_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12872-024-04103-7","volume":"24","author":"A Elshahat","year":"2024","unstructured":"Elshahat\u00a0A et\u00a0al (2024) Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a\u00a0systematic review and meta-analysis. BMC Cardiovasc Disord 24(1):489","journal-title":"BMC Cardiovasc Disord"},{"issue":"12","key":"2016_CR8","first-page":"1808","volume":"39","author":"RD Feldman","year":"2023","unstructured":"Feldman\u00a0RD et\u00a0al (2023) Revising the Roles of Aldosterone in Vascular Physiology and Pathophysiology: From Electocortin to Baxdrostat. Can J Cardiol 39(12):1808\u20131815","journal-title":"Can J Cardiol"},{"key":"2016_CR9","doi-asserted-by":"publisher","first-page":"105332","DOI":"10.1016\/j.phrs.2020.105332","volume":"163","author":"L Lenzini","year":"2021","unstructured":"Lenzini\u00a0L et\u00a0al (2021) Aldosterone synthase inhibitors for cardiovascular diseases: A\u00a0comprehensive review of preclinical, clinical and in silico data. Pharmacol Res 163:105332","journal-title":"Pharmacol Res"},{"issue":"1","key":"2016_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/13543776.2021.1965991","volume":"32","author":"J Wu","year":"2022","unstructured":"Wu\u00a0J, Ding\u00a0X, Tan\u00a0X (2022) A\u00a0patent review of aldosterone synthase inhibitors (2014-present). Expert Opin Ther Pat 32(1):13\u201328","journal-title":"Expert Opin Ther Pat"},{"key":"2016_CR11","doi-asserted-by":"crossref","unstructured":"Cicero AFG et\u00a0al (2025) Aldosterone Synthase Inhibitors for Resistant Hypertension: Pharmacological Insights\u2014A Systematic Review. Drugs","DOI":"10.1007\/s40265-025-02229-2"},{"issue":"5","key":"2016_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman\u00a0MW et\u00a0al (2023) Phase\u00a02 trial of Baxdrostat for treatment-resistant hypertension. N\u00a0Engl J Med 388(5):395\u2013405","journal-title":"N Engl J Med"},{"key":"2016_CR13","doi-asserted-by":"crossref","unstructured":"Flack JM et\u00a0al (2025) Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase\u00a03 clinical trials BaxHTN, BaxAsia, and Bax24. Hypertens Res","DOI":"10.1038\/s41440-025-02297-7"},{"key":"2016_CR14","doi-asserted-by":"crossref","unstructured":"Dwyer JP et\u00a0al (2025) Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A\u00a0Randomized, Double-Blind, Placebo-Controlled Trial. J\u00a0Am Soc Nephrol","DOI":"10.1681\/ASN.0000000849"},{"key":"2016_CR15","doi-asserted-by":"crossref","unstructured":"Turcu AF et\u00a0al (2025) Phase\u00a02a\u00a0Study\u00a0of Baxdrostat in Primary Aldosteronism. N\u00a0Engl J Med","DOI":"10.1056\/NEJMc2508629"},{"issue":"12","key":"2016_CR16","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","volume":"330","author":"LJ Laffin","year":"2023","unstructured":"Laffin\u00a0LJ et\u00a0al (2023) Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial. JAMA 330(12):1140\u20131150","journal-title":"JAMA"},{"issue":"18","key":"2016_CR17","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","volume":"392","author":"LJ Laffin","year":"2025","unstructured":"Laffin\u00a0LJ et\u00a0al (2025) Lorundrostat efficacy and safety in patients with uncontrolled hypertension. N\u00a0Engl J Med 392(18):1813\u20131823","journal-title":"N Engl J Med"},{"key":"2016_CR18","unstructured":"Saxena M et\u00a0al (2025) Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial. JAMA 5: 409-418"},{"issue":"10424","key":"2016_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle\u00a0KR et\u00a0al (2024) Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a\u00a0randomised, controlled, phase\u00a02\u00a0trial. Lancet 403(10424):379\u2013390","journal-title":"Lancet"},{"key":"2016_CR20","doi-asserted-by":"publisher","first-page":"102576","DOI":"10.1016\/j.eclinm.2024.102576","volume":"71","author":"P Mulatero","year":"2024","unstructured":"Mulatero\u00a0P et\u00a0al (2024) Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a\u00a0randomised, parallel group, multicentre, phase\u00a02\u00a0trial. EClinicalMedicine 71:102576","journal-title":"EClinicalMedicine"},{"key":"2016_CR21","unstructured":"Kidney Week Abstract THPO1121, JASN 2023. https:\/\/www.asn-online.org\/education\/kidneyweek\/archives\/?scroll_to=kw_2023"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-02016-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-02016-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-02016-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:15:27Z","timestamp":1774361727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-02016-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,9]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2016"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-02016-x","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,9]]},"assertion":[{"value":"17 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Vortr\u00e4ge f\u00fcr Bayer, Vifor, AstraZeneca, Akademie der deutschen Hochdruckliga, Boehringer, NovoNordisk und Apontis an. Beratungen: Pharvaris, Nephrolyx, Apontis, AstraZeneca und Merck. Adboards: Bayer, Boehringer und AstraZeneca.\nFirmenbeteiligung: Nephrolyx. Fachgesellschaften: Vorsitzender der Deutschen Hochdruckliga.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}